文献速递甲状腺疾病

与SARS-CoV-2疫苗和COVID-19相关的亚急性甲状腺炎(THYROVAC研究):一项全国性多中心研究

Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究为土耳其53个内分泌中心参与的全国性多中心回顾性队列研究,纳入811例亚急性甲状腺炎患者,分为COVID-19相关组(98例)、SARS-CoV-2疫苗相关组(258例)和对照组(455例)。三组在实验室和影像学表现上无差异,亚急性甲状腺炎的病因不是复发或甲状腺功能减退的独立预测因素。COVID-19和SARS-CoV-2疫苗相关的亚急性甲状腺炎可按经典亚急性甲状腺炎进行治疗和随访。

要点

  • COVID-19相关和疫苗相关亚急性甲状腺炎与经典亚急性甲状腺炎在随访参数和结局上无差异。
  • 年轻年龄和需要糖皮质激素治疗是全队列中亚急性甲状腺炎复发的显著预测因素。
  • 亚急性甲状腺炎起病时C反应蛋白升高、女性、抗甲状腺过氧化物酶(TPO)抗体阴性及未使用糖皮质激素是发生(早期)甲状腺功能减退的显著预测因素。

核心结论

  • COVID-19相关和SARS-CoV-2疫苗相关亚急性甲状腺炎在随访参数和结局上与经典亚急性甲状腺炎无差异,可按经典亚急性甲状腺炎进行治疗和随访。
  • 复发由年轻年龄和需要糖皮质激素治疗决定。
  • 糖皮质激素治疗独立预测可能有时为短暂性的(早期)甲状腺功能减退,也与已确立的甲状腺功能减退风险较低相关。

研究设计与样本

  • 全国性、多中心、回顾性队列研究,纳入土耳其53个内分泌中心。
  • 参与者分为COVID-19相关亚急性甲状腺炎组(Cov-SAT)、SARS-CoV-2疫苗相关亚急性甲状腺炎组(Vac-SAT)和对照组亚急性甲状腺炎组(Cont-SAT)。
  • 共纳入811例患者。

主要发现

  • 811例患者中,Vac-SAT组258例(31.8%),Cov-SAT组98例(12.1%),Cont-SAT组455例(56.1%)。
  • 各组间实验室和影像学表现无差异。
  • 亚急性甲状腺炎病因不是复发或甲状腺功能减退的独立预测因素。
  • 在全队列中,需要糖皮质激素治疗和年轻年龄是亚急性甲状腺炎复发的统计学显著预测因素。
  • 亚急性甲状腺炎起病时测得的C反应蛋白、女性、抗甲状腺过氧化物酶(TPO)抗体阴性及未使用糖皮质激素是发生(早期)甲状腺功能减退的统计学显著预测因素,与亚急性甲状腺炎病因无关;已确立的甲状腺功能减退的可能预测因素与(早期)甲状腺功能减退不同。

关键数值与推荐

  • 复发预测因素:年轻年龄和需要糖皮质激素治疗(全队列中统计学显著)。
  • (早期)甲状腺功能减退预测因素:起病时C反应蛋白、女性、抗TPO抗体阴性、未使用糖皮质激素(统计学显著,与病因无关)。

临床怎么用

  • COVID-19相关和SARS-CoV-2疫苗相关亚急性甲状腺炎可按经典亚急性甲状腺炎进行治疗和随访。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The aims of the study are to compare characteristics of subacute thyroiditis (SAT) related to different etiologies, and to identify predictors of recurrence of SAT and incident hypothyroidism. METHODS: This nationwide, multicenter, retrospective cohort study included 53 endocrinology centers in Turkey. The study participants were divided into either COVID-19-related SAT (Cov-SAT), SARS-CoV-2 vaccine-related SAT (Vac-SAT), or control SAT (Cont-SAT) groups. RESULTS: Of the 811 patients, 258 (31.8%) were included in the Vac-SAT group, 98 (12.1%) in the Cov-SAT group, and 455 (56.1%) in the Cont-SAT group. No difference was found between the groups with regard to laboratory and imaging findings. SAT etiology was not an independent predictor of recurrence or hypothyroidism. In the entire cohort, steroid therapy requirement and younger age were statistically significant predictors for SAT recurrence. C-reactive protein measured during SAT onset, female sex, absence of antithyroid peroxidase (TPO) positivity, and absence of steroid therapy were statistically significant predictors of incident (early) hypothyroidism, irrespective of SAT etiology. On the other hand, probable predictors of established hypothyroidism differed from that of incident hypothyroidism. CONCLUSION: Since there is no difference in terms of follow-up parameters and outcomes, COVID-19- and SARS-CoV-2 vaccine-related SAT can be treated and followed up like classic SATs. Recurrence was determined by younger age and steroid therapy requirement. Steroid therapy independently predicts incident hypothyroidism that may sometimes be transient in overall SAT and is also associated with a lower risk of established hypothyroidism.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Batman A, Yazıcı D, Dikbaş O, et al. Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study. J Clin Endocrinol Metab. 2023. PMID: 37186260. doi:10.1210/clinem/dgad235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。